A Prospective Study of Neurologic Disorders in Hospitalized Patients With COVID-19 in New York City
Jennifer Frontera, Sakinah Sabadia, Rebecca Lalchan, Taolin Fang, Brent Flusty, Patricio Millar Vernetti, Thomas E. Snyder, S Berger, Dixon Yang, Andre Granger, Nicole Morgan, Palak Patel, Josef Gutman, Kara Melmed, Shashank Agarwal, Matthew Bokhari, Andres Andino, Eduard Valdes, Mirza Omari, Alexandra Kvernland, Kaitlyn Lillemoe, Sherry Chou, Molly McNett, Raimund Helbok, Shraddha Mainali, Ericka L. Fink, Courtney Robertson, Michelle E. Schober, José I. Suarez, Wendy Ziai, David Menon, Daniel Friedman, David Friedman, Manisha Holmes, Joshua Zhexue Huang, Sujata Thawani, Jonathan Howard, Nada Abou-Fayssal, Penina Krieger, Ariane Lewis, Aaron Lord, Ting Zhou, D. Ethan Kahn, Barry Czeisler, Jose Torres, Shadi Yaghi, Koto Ishida, Erica Scher, Adam de Havenon, Dimitris G. Placantonakis, Mengling Liu, Thomas Wısnıewskı, Andrea B. Troxel, Laura J. Balcer, Steven Galetta
Abstract
OBJECTIVE: To determine the prevalence and associated mortality of well-defined neurologic diagnoses among patients with coronavirus disease 2019 (COVID-19), we prospectively followed hospitalized severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-positive patients and recorded new neurologic disorders and hospital outcomes. METHODS: We conducted a prospective, multicenter, observational study of consecutive hospitalized adults in the New York City metropolitan area with laboratory-confirmed SARS-CoV-2 infection. The prevalence of new neurologic disorders (as diagnosed by a neurologist) was recorded and in-hospital mortality and discharge disposition were compared between patients with COVID-19 with and without neurologic disorders. RESULTS: < 0.001). CONCLUSIONS: Neurologic disorders were detected in 13.5% of patients with COVID-19 and were associated with increased risk of in-hospital mortality and decreased likelihood of discharge home. Many observed neurologic disorders may be sequelae of severe systemic illness.